New hepatitis C therapies in clinical development

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Current standard of care for chronic hepatitis C (HCV) using pegylated interferon alfa and ribavirin achieves sustained virologic response (SVR) in only about 50% of patients.
• Advances in understanding the HCV life cycle have identified new targets for direct-acting antiviral (DAA) drug development.

Purpose of the Study:

• To review the development and clinical progress of novel direct-acting antiviral compounds targeting hepatitis C virus.
• To highlight emerging therapeutic strategies and future directions for HCV treatment.

Main Methods:

• Review of clinical trial data for direct-acting antiviral agents targeting HCV.
• Analysis of emerging mechanisms of action and future treatment possibilities.

Main Results:

• Protease inhibitors (telaprevir, boceprevir) combined with standard of care yielded SVR rates of 66-75% in treatment-naive and 59-66% in treatment-experienced patients with HCV genotype 1.
• Inhibitors of HCV NS5A protein and NS5B polymerase show promise across genotypes in early studies.
• Second-generation protease inhibitors are under development with potentially improved profiles.

Conclusions:

• Direct-acting antivirals, particularly protease inhibitors, significantly improve SVR rates for HCV genotype 1 infection compared to standard therapy.
• Emerging DAAs targeting NS5A and NS5B, along with other mechanisms, offer broader genotypic activity and potential for interferon-free regimens.
• Future HCV treatment strategies are moving towards combinations of DAAs, aiming for highly effective, interferon-free therapies.